Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARGX | 6-K | bullish | 8/10 | Argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune | Aug 17, 2026 |
| PLUR | PRESS-RELEASE | neutral | 4/10 | Pluri's majority-owned food-tech subsidiary, Ever After Foods (EAF), has acquired Fishway BV, a Belgian aquatic cell bio | Aug 17, 2026 |
| DARE | 8-K | bearish | 7/10 | Dare Bioscience entered into a securities purchase agreement on August 14, 2026, for a ~$6.0M public offering of common | Aug 17, 2026 |
| DARE | 424B5 | bearish | 7/10 | Dare Bioscience priced a ~$6.0M public offering of 4,085,687 shares of common stock and 293,894 pre-funded warrants at $ | Aug 17, 2026 |
| DRMA | 8-K | bearish | 7/10 | Dermata Therapeutics entered into a securities purchase agreement for a ~$3.36M private placement, issuing shares, pre-f | Aug 17, 2026 |
| FULC | 8-K | bullish | 8/10 | Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in a reverse-merger tr | Aug 17, 2026 |
| AVXL | 8-K | neutral | 3/10 | Anavex Life Sciences filed an 8-K on August 17, 2026, mailing a letter to stockholders and launching VoteAnavex.com to e | Aug 17, 2026 |
| SVA | 6-K | bearish | 6/10 | Sinovac reported H1 2026 unaudited results: sales grew 12.9% YoY to $147.1M, driven by 82.3% overseas revenue growth, bu | Aug 17, 2026 |
| RADX | 6-K | mixed | 6/10 | Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA scheduled for October 1, 2026, to align on a pi | Aug 17, 2026 |
| EVAX | 6-K | neutral | 4/10 | Evaxion announced a pipeline refocusing, adding a new glioblastoma vaccine program (EVX-05) in collaboration with Duke U | Aug 17, 2026 |
| NSRX | PRESS-RELEASE | neutral | 5/10 | Nasus Pharma reported a net loss of $5.9M for H1 2026, widening from $1.3M in H1 2025, driven by increased R&D and G&A c | Aug 17, 2026 |
| AURX | 8-K | bullish | 5/10 | Nuo Therapeutics reported Q2 2026 revenue of ~$1.77M, up >150% YoY, and a net operating loss of ~$167K, improved by ~$28 | Aug 17, 2026 |
| NRXP | 8-K | bullish | 7/10 | NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months ended June 30, 2026, | Aug 17, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced positive Phase III SAFFRON trial results showing Tagrisso plus Orpathys significantly improved pro | Aug 17, 2026 |
| KMDA | 6-K, PRESS-RELEASE | bullish | 6/10 | Kamada Ltd. reported record-high revenue and profitability for the first six months of 2026 and declared a cash dividend | Aug 17, 2026 |
| ZURA | 8-K | neutral | 5/10 | Zura Bio filed an 8-K furnishing an updated corporate investor presentation (Exhibit 99.1) as Regulation FD disclosure. | Aug 17, 2026 |
| RADX | PRESS-RELEASE | bullish | 7/10 | Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 tri | Aug 17, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) a | Aug 17, 2026 |
| RDY | 6-K | mixed | 5/10 | Dr. Reddy's filed two 6-Ks on August 14, 2026, disclosing USFDA inspection outcomes at two different facilities. The fir | Aug 17, 2026 |
| ADIL | 8-K | bullish | 7/10 | Adial Pharmaceuticals reported Q2 2026 results highlighting a strategic pivot via the acquisition of Azora Therapeutics | Aug 17, 2026 |
| NRXP | PRESS-RELEASE | neutral | 1/10 | NRx Pharmaceuticals, Inc. announced it will host a conference call on August 17 to discuss its Q2 2026 results. | Aug 17, 2026 |
| ADIL | PRESS-RELEASE | neutral | 4/10 | Adial Pharmaceuticals reported Q2 2026 results with a net loss of $52.0M ($11.25 per share), driven by a $46.2M non-cash | Aug 17, 2026 |
| FULC | PRESS-RELEASE | bullish | 8/10 | Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockh | Aug 17, 2026 |
| BMY | INST-CLUSTER | bullish | 6/10 | A powerful institutional cluster formed in BMY during Q2 2026, with 20 buyers accumulating $2.46B net against 8 sellers | Aug 17, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back | Aug 16, 2026 |
| AVXL | INST-CLUSTER | bearish | 5/10 | Anavex Life Sciences saw a mixed institutional cluster in Q2 2026, with 5 small buyers (net +$308K) but 6 sellers cuttin | Aug 16, 2026 |
| ALDX | INST-CLUSTER | bearish | 6/10 | A bearish institutional cluster formed in ALDX during 2026-Q2, with 9 sellers reducing holdings by $6.9M versus 4 buyers | Aug 16, 2026 |
| AVTX | INST-CLUSTER | bullish | 6/10 | Avalo Therapeutics (AVTX) saw a massive institutional accumulation cluster in Q2 2026, with 11 buyers adding $180.7M in | Aug 16, 2026 |
| AMRX | INST-CLUSTER | bullish | 6/10 | A strong institutional accumulation cluster emerged in Amneal Pharmaceuticals during 2026-Q2, with 14 buyers adding a ne | Aug 16, 2026 |
| ACAD | INST-CLUSTER | mixed | 5/10 | Institutional activity in ACAD during 2026-Q2 shows a mixed picture: 12 buyers accumulated $180.5M (net +$122.9M) led by | Aug 16, 2026 |